BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haicheur N, Escudier B, Dorval T, Negrier S, De Mulder PH, Dupuy JM, Novick D, Guillot T, Wolf S, Pouillart P, Fridman WH, Tartour E. Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol 2000;119:28-37. [PMID: 10606961 DOI: 10.1046/j.1365-2249.2000.01112.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Teymouri M, Pirro M, Fallarino F, Gargaro M, Sahebkar A. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases: Immune-regulation in cancer progression. Int J Cancer 2018;143:2105-15. [DOI: 10.1002/ijc.31382] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
2 Rada M, Lazaris A, Kapelanski-Lamoureux A, Mayer TZ, Metrakos P. Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model. Semin Cancer Biol 2021;71:52-64. [PMID: 32920126 DOI: 10.1016/j.semcancer.2020.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Little RF, Aleman K, Kumar P, Wyvill KM, Pluda JM, Read-Connole E, Wang V, Pittaluga S, Catanzaro AT, Steinberg SM, Yarchoan R. Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. Blood 2007;110:4165-71. [PMID: 17846226 DOI: 10.1182/blood-2007-06-097568] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
4 Sabel MS, Su G, Griffith KA, Chang AE. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer. Breast Cancer Res Treat 2010;122:325-36. [PMID: 19802695 DOI: 10.1007/s10549-009-0570-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
5 Oldham RA, Berinstein EM, Medin JA. Lentiviral vectors in cancer immunotherapy. Immunotherapy 2015;7:271-84. [PMID: 25804479 DOI: 10.2217/imt.14.108] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
6 Chauvat A, Benhamouda N, Loison E, Gougeon ML, Gey A, Levionnois E, Ravel P, Abitbol V, Roncelin S, Marcheteau E, Quintin-Colonna F, Fridman WH, Launay O, Tartour E. Pitfalls in anti-influenza T cell detection by Elispot using thimerosal containing pandemic H1N1 vaccine as antigen. J Immunol Methods 2012;378:81-7. [PMID: 22366633 DOI: 10.1016/j.jim.2012.02.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
7 Paoloni M, Mazcko C, Selting K, Lana S, Barber L, Phillips J, Skorupski K, Vail D, Wilson H, Biller B, Avery A, Kiupel M, LeBlanc A, Bernhardt A, Brunkhorst B, Tighe R, Khanna C. Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma. PLoS One 2015;10:e0129954. [PMID: 26091536 DOI: 10.1371/journal.pone.0129954] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
8 Parihar R, Dierksheide J, Hu Y, Carson WE. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 2002;110:983-92. [DOI: 10.1172/jci0215950] [Cited by in Crossref: 87] [Article Influence: 4.4] [Reference Citation Analysis]
9 Baay M, Brouwer A, Pauwels P, Peeters M, Lardon F. Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol. 2011;2011:565187. [PMID: 22162712 DOI: 10.1155/2011/565187] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 7.4] [Reference Citation Analysis]
10 Greiner JW, Morillon YM 2nd, Schlom J. NHS-IL12, a Tumor-Targeting Immunocytokine. Immunotargets Ther 2021;10:155-69. [PMID: 34079772 DOI: 10.2147/ITT.S306150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Maheshwari A, Han S, Mahato R, Kim S. Biodegradable polymer-based interleukin-12 gene delivery: role of induced cytokines, tumor infiltrating cells and nitric oxide in anti-tumor activity. Gene Ther 2002;9:1075-84. [DOI: 10.1038/sj.gt.3301766] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
12 Zhang Q, Liu S, Ge D, Zhang Q, Xue Y, Xiong Z, Abdel-Mageed AB, Myers L, Hill SM, Rowan BG. Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res. 2012;72:2589-2599. [PMID: 22461511 DOI: 10.1182/blood.v99.6.2114] [Cited by in Crossref: 235] [Cited by in F6Publishing: 135] [Article Influence: 23.5] [Reference Citation Analysis]
13 Kim T, Jiang H, Nah J, Cho M, Akaike T, Cho C. Receptor-Mediated Gene Delivery Using Chitosan Derivativesin Vitro andin Vivo. Macromol Symp 2007;249-250:137-44. [DOI: 10.1002/masy.200750323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
14 Wang Y, Lin YX, Qiao SL, Wang J, Wang H. Progress in Tumor-Associated Macrophages: From Bench to Bedside. Adv Biosyst 2019;3:e1800232. [PMID: 32627370 DOI: 10.1002/adbi.201800232] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wouters BG, Weppler SA, Koritzinsky M, Landuyt W, Nuyts S, Theys J, Chiu RK, Lambin P. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002;38:240-57. [PMID: 11803141 DOI: 10.1016/s0959-8049(01)00361-6] [Cited by in Crossref: 131] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
16 Parihar R, Dierksheide J, Hu Y, Carson WE. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 2002;110:983-92. [PMID: 12370276 DOI: 10.1172/JCI15950] [Cited by in Crossref: 11] [Cited by in F6Publishing: 86] [Article Influence: 0.6] [Reference Citation Analysis]
17 Yoshimoto T, Morishima N, Okumura M, Chiba Y, Xu M, Mizuguchi J. Interleukins and cancer immunotherapy. Immunotherapy 2009;1:825-44. [PMID: 20636026 DOI: 10.2217/imt.09.46] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
18 Gu T, Rowswell-Turner RB, Kilinc MO, Egilmez NK. Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity. Cancer Res 2010;70:129-38. [PMID: 20028855 DOI: 10.1158/0008-5472.CAN-09-3170] [Cited by in Crossref: 42] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
19 Chauvat A, Benhamouda N, Gey A, Lemoine FM, Paulie S, Carrat F, Gougeon ML, Rozenberg F, Krivine A, Cherai M, Lehmann P 5th, Quintin-Colonna F, Launay O, Tartour E. Clinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans. Hum Vaccin Immunother 2014;10:104-13. [PMID: 24084262 DOI: 10.4161/hv.26593] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
20 Agrawal R, Dale TP, Al-Zubaidi MA, Benny Malgulwar P, Forsyth NR, Kulshreshtha R. Pluripotent and Multipotent Stem Cells Display Distinct Hypoxic miRNA Expression Profiles. PLoS One 2016;11:e0164976. [PMID: 27783707 DOI: 10.1371/journal.pone.0164976] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
21 Frassanito MA, Cusmai A, Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol 2001;125:190-7. [PMID: 11529908 DOI: 10.1046/j.1365-2249.2001.01582.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 2.8] [Reference Citation Analysis]
22 Mendonça VR, Queiroz AT, Lopes FM, Andrade BB, Barral-Netto M. Networking the host immune response in Plasmodium vivax malaria. Malar J 2013;12:69. [PMID: 23433077 DOI: 10.1186/1475-2875-12-69] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis]
23 Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, Sandoval F, Quintin-Colonna F, Lacerda K, Karadimou A. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011;30:83-95. [PMID: 21249423 DOI: 10.1007/s10555-011-9281-4] [Cited by in Crossref: 208] [Cited by in F6Publishing: 188] [Article Influence: 18.9] [Reference Citation Analysis]
24 Pires IS, Hammond PT, Irvine DJ. Engineering Strategies for Immunomodulatory Cytokine Therapies - Challenges and Clinical Progress. Adv Ther (Weinh) 2021;4:2100035. [PMID: 34734110 DOI: 10.1002/adtp.202100035] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Arianfar E, Shahgordi S, Memarian A. Natural Killer Cell Defects in Breast Cancer: A Key Pathway for Tumor Evasion. Int Rev Immunol 2021;40:197-216. [PMID: 33258393 DOI: 10.1080/08830185.2020.1845670] [Reference Citation Analysis]
26 Coronel A, Boyer A, Franssen JD, Romet-Lemonne JL, Fridman WH, Teillaud JL. Cytokine production and T-cell activation by macrophage-dendritic cells generated for therapeutic use. Br J Haematol 2001;114:671-80. [PMID: 11552997 DOI: 10.1046/j.1365-2141.2001.02982.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
27 Jouan J, Golmard L, Benhamouda N, Durrleman N, Golmard JL, Ceccaldi R, Trinquart L, Fabiani JN, Tartour E, Jeunemaitre X, Menasché P. Gene polymorphisms and cytokine plasma levels as predictive factors of complications after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2012;144:467-73, 473.e1-2. [PMID: 22264418 DOI: 10.1016/j.jtcvs.2011.12.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
28 Mitola S, Strasly M, Prato M, Ghia P, Bussolino F. IL-12 regulates an endothelial cell-lymphocyte network: effect on metalloproteinase-9 production. J Immunol 2003;171:3725-33. [PMID: 14500672 DOI: 10.4049/jimmunol.171.7.3725] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 2.4] [Reference Citation Analysis]
29 Ansari AA, Mayne AE, Sundstrom JB, Bostik P, Grimm B, Altman JD, Villinger F. Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques. J Virol 2002;76:1731-43. [PMID: 11799168 DOI: 10.1128/jvi.76.4.1731-1743.2002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
30 Jahromi M, Al-Otaibi T, Ashry Gheith O, Farouk Othman N, Mahmoud T, Nair P, A-Halim M, Aggarwal P, Messenger G, Chu P, De Serres SA, Azzi JR. Analysis of the frequency of single nucleotide polymorphisms in cytokine genes in patients with New Onset Diabetes After Transplant. Sci Rep 2021;11:6014. [PMID: 33727573 DOI: 10.1038/s41598-021-84400-9] [Reference Citation Analysis]
31 Choi IK, Li Y, Oh E, Kim J, Yun CO. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity. PLoS One 2013;8:e67512. [PMID: 23844018 DOI: 10.1371/journal.pone.0067512] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
32 Karsten MM, Enders S, Knabl J, Kirn V, Düwell P, Rack B, Blohmer JU, Mayr D, Dian D. Biologic meshes and synthetic meshes in cancer patients: a double-edged sword: differences in production of IL-6 and IL-12 caused by acellular dermal matrices in human immune cells. Arch Gynecol Obstet 2018;297:1265-70. [PMID: 29417284 DOI: 10.1007/s00404-018-4710-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 2007;7:1705-21. [PMID: 17961093 DOI: 10.1517/14712598.7.11.1705] [Cited by in Crossref: 148] [Cited by in F6Publishing: 125] [Article Influence: 9.9] [Reference Citation Analysis]
34 Hernandez-Alcoceba R, Poutou J, Ballesteros-Briones MC, Smerdou C. Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12. Immunotherapy 2016;8:179-98. [PMID: 26786809 DOI: 10.2217/imt.15.109] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
35 Awad RM, De Vlaeminck Y, Maebe J, Goyvaerts C, Breckpot K. Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. Front Immunol 2018;9:1977. [PMID: 30233579 DOI: 10.3389/fimmu.2018.01977] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 16.0] [Reference Citation Analysis]
36 Tartour E, Sandoval F, Bonnefoy JY, Fridman WH. [Cancer immunotherapy: recent breakthroughs and perspectives]. Med Sci (Paris) 2011;27:833-41. [PMID: 22027420 DOI: 10.1051/medsci/20112710011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
37 Lasek W, Zagożdżon R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 2014;63:419-35. [PMID: 24514955 DOI: 10.1007/s00262-014-1523-1] [Cited by in Crossref: 218] [Cited by in F6Publishing: 203] [Article Influence: 27.3] [Reference Citation Analysis]
38 Shi G, Edelblute C, Arpag S, Lundberg C, Heller R. IL-12 Gene Electrotransfer Triggers a Change in Immune Response within Mouse Tumors. Cancers (Basel) 2018;10:E498. [PMID: 30544810 DOI: 10.3390/cancers10120498] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
39 Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol 2010;2010:832454. [PMID: 20885915 DOI: 10.1155/2010/832454] [Cited by in Crossref: 82] [Cited by in F6Publishing: 92] [Article Influence: 6.8] [Reference Citation Analysis]
40 Kim T, Jiang H, Jere D, Park I, Cho M, Nah J, Choi Y, Akaike T, Cho C. Chemical modification of chitosan as a gene carrier in vitro and in vivo. Progress in Polymer Science 2007;32:726-53. [DOI: 10.1016/j.progpolymsci.2007.05.001] [Cited by in Crossref: 236] [Cited by in F6Publishing: 176] [Article Influence: 15.7] [Reference Citation Analysis]
41 Santana MA, Rosenstein Y. What it takes to become an effector T cell: the process, the cells involved, and the mechanisms. J Cell Physiol 2003;195:392-401. [PMID: 12704648 DOI: 10.1002/jcp.10258] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 3.5] [Reference Citation Analysis]
42 Kim TH, Jin H, Kim HW, Cho MH, Nah JW, Cho CS. Receptor-Mediated Gene Delivery Using Chitosan Derivatives In Vitro and In Vivo. KEM 2007;342-343:449-52. [DOI: 10.4028/www.scientific.net/kem.342-343.449] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
43 Ribatti D. Angiogenic activity of classical hematopoietic cytokines. Leuk Res 2012;36:537-43. [PMID: 22386730 DOI: 10.1016/j.leukres.2012.02.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]